Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like B*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264959410	0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTIONInjectable, 400mg/100mL500mL	05/01/2020	38.95	187.27	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264959820	0.8% LIDOCAINE HCL AND DEXTROSE INJECTIONInjectable, 800mg/100mL250mL	05/01/2020	53.61	170.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264180032	0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900 mg/mL100mL	05/01/2020	24.32	145.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264180036	0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900 mg/mL25mL	05/01/2020	56.40	244.39	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264180031	0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900 mg/mL50mL	05/01/2020	31.92	190.68	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264780020	0.9% SODIUM CHLORIDE INJECTION USPInjectable, 900mg/100mL250mL	05/01/2020	2.58	57.54	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264762320	10% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USPInjectable, 10gm/100mL Dextrose; 200mg/100mL Sodium Chloride250mL	05/01/2020	19.98	74.92	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264752000	10% DEXTROSE INJECTION USPInjectable, 10gm/100mL1000mL	05/01/2020	8.55	37.06	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264752010	10% DEXTROSE INJECTION USPInjectable, 10gm/100mL500mL	05/01/2020	15.38	66.63	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264320055	15% AMINO ACIDS INJECTION PHARMACY BULK PACKAGEInjectable, 15% (150gm/1000mL)1000mL	05/01/2020	36.53	211.54	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264151031	5% DEXTROSE INJECTION USP;Injectable, 50 mg/mL;50mL	05/01/2020	31.92	190.68	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264151032	5% DEXTROSE INJECTION USPInjectable, 50 mg/mL100mL	05/01/2020	24.32	145.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264751000	5% DEXTROSE INJECTION USPInjectable, 5gm/100mL1000mL	05/01/2020	7.47	44.31	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264751020	5% DEXTROSE INJECTION USPInjectable, 5gm/100mL250mL	05/01/2020	18.39	68.47	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264751010	5% DEXTROSE INJECTION USPInjectable, 5gm/100mL500mL	05/01/2020	22.10	74.51	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264738750	70% DEXTROSE INJECTION USPInjectable, 70gm/100mL2000mL	05/01/2020	13.20	57.21	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264310311	CEFAZOLIN 1G 50ML ISO-OSMOTIC DEXINJ DUPLEX DRUG DEL SYSTEMEq 1gm base/vial50mL	05/01/2020	52.56	272.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264310511	CEFAZOLIN FOR INJECTION USP AND DEXTROSE INJECTION USP IN THEEq 2gm base/vial50mL	05/01/2020	31.89	306.45	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264319311	CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEXInjectable, Eq 1gm base/vial50mL	05/01/2020	26.28	408.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264317311	CEFOTETAN FOR INJECTION AND DEXTROSE INJECTIONInjectable, Eq 1gm base/vial50mL	05/01/2020	109.44	544.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264317511	CEFOTETAN FOR INJECTION AND DEXTROSE INJECTIONInjectable, Eq 2gm base/vial50mL	05/01/2020	143.56	766.12	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264312311	CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINERInjectable, Eq 1gm base/vial50mL	05/01/2020	87.25	391.57	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264312511	CEFOXITIN FOR INJECTION IN THE DUPLEX CONTAINERInjectable, Eq 2gm base/vial50mL	05/01/2020	142.71	701.43	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264314311	CEFTAZIDIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEXInjectable, Eq 1gm base/vial50mL	05/01/2020	16.95	374.55	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264314511	CEFTAZIDIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEXInjectable, Eq 2gm base/vial50mL	05/01/2020	110.89	527.77	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264315311	CEFTRIAXONE FOR INJECTION AND DEXTROSE INJECTION IN DUPLEXInjectable, Eq 1gm base/vial50mL	05/01/2020	47.88	408.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264957710	HEPARIN IN DEXTROSE INJECTION4,000 Units/100mL500mL	05/01/2020	33.48	354.12	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264987210	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTICInjectable. 200 units/100mL500mL	05/01/2020	6.49	91.93	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264956710	HEPARIN SODIUM IN 5% DEXTROSE INJECTION (500 U/ML)5,000 Units/100mL500mL DEX	05/01/2020	59.52	299.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264937155	HEPATAMINEInjectable, 8% (8gm/100mL)500mL	05/01/2020	60.23	624.61	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264553532	METRO IV (METRONIDAZOLE INJECTION 0.5%)Injectable, 500mg/100mL100mL	05/01/2020	20.96	71.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264446030	NUTRILIPID 20%Injectable, 20%250mL	05/01/2020	57.69	255.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264446010	NUTRILIPID 20%Injectable, 20%500mL	05/01/2020	58.51	323.47	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264738850	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERSoultion, 900mg/100mL2000mL	05/01/2020	11.57	46.53	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264738860	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERSoultion, 900mg/100mL3000mL	05/01/2020	10.06	62.42	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264785000	STERILE WATER FOR INJECTION USPLiquid, 100%1000mL	05/01/2020	9.90	41.69	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264738660	STERILE WATER FOR IRRIGATION USPLiquid, 100%3000mL	05/01/2020	11.58	65.26	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	06/30/2020	00264934155	TROPHAMINE 10%10% (10gm/100mL)500mL	05/01/2020	48.52	211.54	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun within the last 5 years.
Rx0000229	B. F. ASCHER AND COMPANY, INC.	03/31/2020	00225029520	Anaspaz 0.125 mg Tablets 500ct	02/01/2020	18.50	122.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208035310	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL	01/09/2020	27.07	478.26	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208035305	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL	01/09/2020	13.54	239.14	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208062901	BEPREVE™ Ophthalmic Solution USP, 1.5%, 10mL	01/09/2020	24.91	440.09	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208062902	BEPREVE™ Ophthalmic Solution USP, 1.5%, 5mL	01/09/2020	13.02	230.10	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208044605	BESIVANCE® (besifloxacin ophthalmic suspension 0.6%)	01/09/2020	10.16	179.52	01/09/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208000401	ISTALOL™ Ophthalmic Solution USP, 0.5%, 2.5mL	01/09/2020	10.35	182.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208000403	ISTALOL™ Ophthalmic Solution USP, 0.5%, 5mL	01/09/2020	20.69	365.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208080060	LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg	01/09/2020	30.08	531.44	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/5/2016 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208050307	LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%)	01/09/2020	11.44	202.17	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208044335	LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%)	01/09/2020	16.10	284.48	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208029910	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL	01/09/2020	28.52	503.91	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208029915	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL	01/09/2020	42.41	749.19	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208029905	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL	01/09/2020	14.26	251.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208060203	PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL	01/09/2020	16.00	282.67	11/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208081205	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.25%, 5mL	01/09/2020	10.44	184.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/26/2018 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208081310	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 10mL	01/09/2020	14.48	255.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/26/2018 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208081305	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 5mL	01/09/2020	11.30	199.64	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 2/26/2018 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208081425	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL	01/09/2020	12.22	215.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 11/6/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208081605	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL	01/09/2020	13.39	236.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that acquisition date of Aton Pharma, Inc. which was previously reported as 8/19/2015 was incorrect. The correct acquisition date is 9/1/2010 and therefore, per the reporting requirements, is no longer included. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208053535	ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%)	01/09/2020	21.08	372.34	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208035810	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL	01/09/2020	29.69	524.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2020	24208035805	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL	01/09/2020	14.84	262.23	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385002260	Belbuca 150 mcg, film, 60ct box	01/01/2020	16.61	348.82	12/21/2032	Single Source Drug	None	1	None	1	None	1	01/06/2017	Endo Pharmaceuticals	7536000	None	Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760.	278.60	255.60	2015	255.60	None	None
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385002360	Belbuca 300 mcg, film, 60ct box	01/01/2020	26.09	547.83	12/21/2032	Single Source Drug	None	1	None	1	None	1	01/06/2017	Endo Pharmaceuticals	7536000	None	Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760.	437.53	401.40	2015	401.40	None	None
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385002460	Belbuca 450 mcg, film, 60ct box	01/01/2020	35.45	744.36	12/21/2032	Single Source Drug	None	1	None	1	None	1	01/06/2017	Endo Pharmaceuticals	7536000	None	Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760.	594.49	545.40	2015	545.40	None	None
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385002560	Belbuca 600 mcg, film, 60ct box	01/01/2020	37.82	794.29	12/21/2032	Single Source Drug	None	1	None	1	None	1	01/06/2017	Endo Pharmaceuticals	7536000	None	Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760.	634.38	582.00	2015	582.00	None	None
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385002160	Belbuca 75 mcg, film, 60ct box	01/01/2020	16.61	348.82	12/21/2032	Single Source Drug	None	1	None	1	None	1	01/06/2017	Endo Pharmaceuticals	7536000	None	Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760.	278.60	255.60	2015	255.60	None	None
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385002660	Belbuca 750 mcg, film, 60ct box	01/01/2020	39.77	835.24	12/21/2032	Single Source Drug	None	1	None	1	None	1	01/06/2017	Endo Pharmaceuticals	7536000	None	Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760.	667.08	612.00	2015	612.00	None	None
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385002760	Belbuca 900 mcg, film, 60ct box	01/01/2020	40.94	859.80	12/21/2032	Single Source Drug	None	1	None	1	None	1	01/06/2017	Endo Pharmaceuticals	7536000	None	Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760.	686.70	630.00	2015	630.00	None	None
Rx0000233	BioDelivery Sciences International, Inc.	03/31/2020	59385004130	Symproic .2mg mg tablet, 30 ct bottle	01/01/2020	17.96	377.11	11/11/2031	Single Source Drug	None	1	None	1	None	1	04/04/2019	Shionogi Inc.	30000000	None	None	359.15	313.95	2017	313.95	None	None
Rx0000099	Biogen	03/31/2020	64406000501	Tecfidera (dimethyl fumarate) Half Dose (120 mg) Capsules: 7-day bottle of 14 capsules	01/01/2020	109.30	1931.10	02/07/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2020	64406000602	Tecfidera (dimethyl fumarate) Regular Dose (240 mg) Capsules: 30-day bottle of 60 capsules	01/01/2020	468.44	8275.89	02/07/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2020	64406000703	Tecfidera (dimethyl fumarate) Starter Pack (30 day): 7-day bottle 120 mg capsules, quantity 14 and 23-day bottle 240 mg capsules, quantity 46	01/01/2020	468.44	8275.89	02/07/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	09/30/2020	64406000801	TYSABRI (natalizumab) Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial	07/03/2020	239.81	7091.68	03/05/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tysabri was not acquired by Biogen from another company in the last 5 years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597000201	APTIVUS 100 MG/ML SOLUTION	01/01/2020	33.46	591.09	04/29/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=347	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597000302	APTIVUS 250 MG CAPSULE	01/01/2020	100.38	1773.36	04/29/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=348	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597008717	ATROVENT 17 MCG HFA INHALER	01/01/2020	23.29	411.39	01/17/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=357	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597003134	CATAPRES-TTS 1 PATCH	01/01/2020	15.80	279.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=352	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597003234	CATAPRES-TTS 2 PATCH	01/01/2020	26.80	469.91	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=353	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597003334	CATAPRES-TTS 3 PATCH	01/01/2020	36.90	651.86	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=354	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597002402	COMBIVENT RESPIMAT 20-100 MCG	01/01/2020	24.14	426.45	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=349	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014130	GILOTRIF 20 MG TABLET	01/01/2020	704.57	9511.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=372	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597013730	GILOTRIF 30 MG TABLET	01/01/2020	704.57	9511.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=367	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597013830	GILOTRIF 40 MG TABLET	01/01/2020	704.57	9511.72	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=368	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015237	JARDIANCE 10 MG 30 TABLET	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=380	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015230	JARDIANCE 10 MG TABLET 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=379	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015290	JARDIANCE 10 MG TABLET 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=381	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015337	JARDIANCE 25 MG 30 TABLET	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=383	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015330	JARDIANCE 25 MG TABLET 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=382	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015390	JARDIANCE 25 MG TABLET 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=384	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014818	JENTADUETO 2.5 MG-1,000 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=377	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014860	JENTADUETO 2.5 MG-1,000 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=378	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014618	JENTADUETO 2.5 MG-500 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=373	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014660	JENTADUETO 2.5 MG-500 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=374	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014718	JENTADUETO 2.5 MG-850 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=375	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014760	JENTADUETO 2.5 MG-850 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=376	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597027094	JENTADUETO XR 2.5 MG-1,000 MG 180	01/01/2020	78.51	1387.02	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=397	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597027073	JENTADUETO XR 2.5 MG-1,000 MG 60	01/01/2020	26.17	462.34	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=396	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597027533	JENTADUETO XR 5 MG-1,000 MG TB 30	01/01/2020	26.17	462.34	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=398	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597027581	JENTADUETO XR 5 MG-1,000 MG TB 90	01/01/2020	78.51	1387.02	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=399	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597010930	MIRAPEX ER 0.375 MG TABLET 30	01/01/2020	35.87	633.73	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=362	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597010917	MIRAPEX ER 0.375 MG TABLET 7	01/01/2020	8.37	147.85	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=361	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597028530	MIRAPEX ER 0.75 MG TABLET 30	01/01/2020	35.87	633.73	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=403	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597028517	MIRAPEX ER 0.75 MG TABLET 7	01/01/2020	8.37	147.85	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=402	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597011330	MIRAPEX ER 1.5 MG TABLET 30	01/01/2020	35.87	633.73	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=364	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597011317	MIRAPEX ER 1.5 MG TABLET 7	01/01/2020	8.37	147.85	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=363	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597028630	MIRAPEX ER 2.25 MG TABLET	01/01/2020	35.87	633.73	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=404	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597011530	MIRAPEX ER 3 MG TABLET	01/01/2020	35.87	633.73	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=365	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597028730	MIRAPEX ER 3.75 MG TABLET	01/01/2020	35.87	633.73	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=405	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597011630	MIRAPEX ER 4.5 MG TABLET	01/01/2020	35.87	633.73	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=366	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597003001	MOBIC 15 MG TABLET	01/01/2020	77.42	1367.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=351	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597002901	MOBIC 7.5 MG TABLET	01/01/2020	50.63	894.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=350	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014360	OFEV 100 MG CAPSULE 60s	01/01/2020	593.46	10484.53	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014560	OFEV 150MG CAPSULE 60s	01/01/2020	593.46	10484.53	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597010854	PRADAXA 110 MG CAPSULE 60	01/01/2020	25.96	458.58	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=359	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597010860	PRADAXA 110 MG CAPSULE 60 BOTTLE	01/01/2020	25.96	458.58	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=360	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597036082	PRADAXA 150 MG 60 CAPSULE	01/01/2020	25.96	458.58	06/14/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=415	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. 00597-0360-82 replaced 00597-0135-60.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597036055	PRADAXA 150 MG CAPSULE 60	01/01/2020	25.96	458.58	06/14/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=414	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597035556	PRADAXA 75 MG 60 CAPSULE	01/01/2020	25.96	458.58	06/14/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=413	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597035509	PRADAXA 75 MG CAPSULE 60	01/01/2020	25.96	458.58	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=412	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597007541	SPIRIVA 18 MCG CP-HANDIHALER 30	01/01/2020	25.77	455.24	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=355	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597007547	SPIRIVA 18 MCG CP-HANDIHALER 90	01/01/2020	77.31	1365.72	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=356	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597016061	SPIRIVA RESPIMAT 1.25 MCG INH	01/01/2020	25.77	455.24	04/16/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=388	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597010061	SPIRIVA RESPIMAT 2.5 MCG INH	01/01/2020	25.77	455.24	04/16/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=358	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015561	STIOLTO RESPIMAT INHAL SPRAY 2.5 MCG-2.5 MCG	01/01/2020	23.86	421.52	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=385	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597019261	STRIVERDI RESPIMAT INHAL SPRAY 2.5 MCG	01/01/2020	12.71	224.54	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=395	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597016818	SYNJARDY 12.5-1,000 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=389	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597016860	SYNJARDY 12.5-1,000 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=390	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597018018	SYNJARDY 12.5-500 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=393	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597018060	SYNJARDY 12.5-500 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=394	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597017518	SYNJARDY 5-1,000 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=391	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597017560	SYNJARDY 5-1,000 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=392	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015918	SYNJARDY 5-500 MG TABLET 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=386	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597015960	SYNJARDY 5-500 MG TABLET 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=387	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597028073	SYNJARDY XR 10 mg-1,000 mg 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=400	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597028090	SYNJARDY XR 10 mg-1,000 mg 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=401	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597030093	SYNJARDY XR 12.5 mg-1,000 mg 180	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=411	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597030045	SYNJARDY XR 12.5 mg-1,000 mg 60	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=410	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597029588	SYNJARDY XR 25 mg-1,000 mg 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=409	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597029578	SYNJARDY XR 25 mg-1,000 mg 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=408	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597029059	SYNJARDY XR 5 mg-1,000 mg 180	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=406	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597029074	SYNJARDY XR 5 mg-1,000 mg 60	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=407	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014061	TRADJENTA 5 MG TABLET 100	01/01/2020	87.23	1541.13	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=370	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014030	TRADJENTA 5 MG TABLET 30	01/01/2020	26.17	462.34	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=369	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2020	00597014090	TRADJENTA 5 MG TABLET 90	01/01/2020	78.51	1387.02	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=371	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000078	Bristol Myers Squibb	03/31/2020	00003089321	ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle of 60 Tablets	01/01/2020	26.65	470.82	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003089331	ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle x 100 Tablets	01/01/2020	44.42	784.76	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003089470	ELIQUIS (Apixaban) 5 MG Tablet Bottle of 74 Tablets	01/01/2020	32.87	580.69	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003376474	ELIQUIS (Apixaban) 5 MG Tablet, 74 Tablets (1 blister pack of 42 tablets and 1 blister pack of 32 tablets)	01/01/2020	32.87	580.69	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003089421	ELIQUIS (Apixaban) 5 MG Tablet, Bottle of 60 Tablets	01/01/2020	26.65	470.82	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003089431	ELIQUIS (Apixaban) 5 MG Tablet, Hospital Unit-Dose Blister Package of 100	01/01/2020	44.42	784.76	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003218851	ORENCIA (Abatacept) 125 MG/ML Solution, 1ML Single Dose Prefilled Auto-injector, Package of 4 Auto-Injectors	01/01/2020	262.73	4641.62	02/18/2028	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003218811	ORENCIA (Abatacept) 125 MG/ML Solution, 1ml Single Dose Prefilled Syringe Package of 4 Syringes	01/01/2020	262.73	4641.62	02/18/2028	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003218710	ORENCIA (Abatacept) 250 MG Solution Vial W/ Syringe, Package contains 1 Vial	01/01/2020	66.54	1175.57	02/18/2028	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003281411	ORENCIA (Abatacept) 50 MG/0.4ML Solution, 0.4ML Single Dose Prefilled Syringe, Package of 4 Syringes	01/01/2020	262.73	4641.62	02/18/2028	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003281811	ORENCIA (Abatacept) 87.5 MG/0.7ML Solution, 0.7ML Single Dose Prefilled Syringe, Package of 4 Syringes	01/01/2020	262.73	4641.62	02/18/2028	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003085222	SPRYCEL (Dasatinib) 100 MG Tablet, Bottle of 30 Tablets	01/01/2020	821.21	14508.00	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003085722	SPRYCEL (Dasatinib) 140 MG Tablet, Bottle of 30 Tablets	01/01/2020	821.21	14508.00	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003052711	SPRYCEL (Dasatinib) 20 MG Tablet, Bottle of 60 Tablets	01/01/2020	455.64	8049.59	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003052811	SPRYCEL (Dasatinib) 50 MG Tablet, Bottle of 60 Tablets	01/01/2020	911.27	16099.14	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003052411	SPRYCEL (Dasatinib) 70 MG Tablet, Bottle of 60 Tablets	01/01/2020	911.27	16099.14	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2020	00003085522	SPRYCEL (Dasatinib) 80 MG Tablet, Bottle of 30 Tablets	01/01/2020	821.21	14508.00	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000131	BTG International Inc.	12/31/2020	50633012011	DigiFab Intravenous Solution Reconstituted 40 MG/vial - 1 vial per carton	10/01/2020	153.00	3974.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None